

The Natural Killer Cell in Anticancer Therapy - An Important Role for Natural Compounds

By Professor Serge Jurasunas, MD(Hom), ND

Complete References

1. Imai K, et al. Natural cytotoxic activity of peripheral blood lymphocyte and cancer incidence - an 11-year follow-up study of a general population. *Lancet*. 2000;356:1795-9.
2. Kruse PH, et al. Natural cytotoxicity receptors and their ligands. *Immunol Cell Biol*. 2014. 92. 221-9.
3. Malruberger K, Carlsten M, Bjorkland A, Schilberg E. Natural killer cell-mediated immunosurveillance of human cancer. *Semin Immunol*. June 2017; 3120-9
4. Bernstein V. Immune Oncology. The 4th pillar of cancer therapy. 20 April 2017. Conference online.
5. Pascuaal M, Rou S. PD1\PD-L1 immune checkpoint and P53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphoma. *Blood*. May 2019;133 (22).
6. Sooyeon Oh, et al. Natural killer cell therapy. A new Treatment Paradydm for solid tumors. *Journal Cancer*. 2019;11(10);1534.
7. Hajto T, Kirich A. Case reports of cancer patients with hepatic metastasis treated with standardized plant immunomodulatory preparations. *Journal of Cancer Research Updates*. 2013.
8. Biron CA, et al. Natural killer cells in antiviral defense. Functions and regulation by innate cytokine. *Ann Rev Immunol*. 1999; 17:189-220.
9. Montaldo E, et al. Human NK cell receptors\markers a tool to analyze NK cell development, subsets, and function. *Cytometry A*, 2013; 83 A:702-13.
10. Pegram HJ, et al. Activating and inhibitory receptors of natural killer cells. *Immunol Cell Biol*. 2011;89:216-224.
11. Ljunggreen HG, Korse K. In search of the missing self-MHC molecules and NK cell recognition. *Immunology Today*. 1990; 11: 237-44.
12. Raule DH. Roles of the NKG2D immunoreceptor and its ligands, *Nat Rev Immunol*. 2003; 781-90.
13. Lusty E, et al. IL18, IL15, IL12 synergy induces elevated and prolonged IFN- γ production by ex vivo expanded NK cells which is not due to enhanced STAT4 activation. *Mol Immunol*. Aug 2017.
14. Kennedy MK, et al.. Reversible defects in Natural Killer and memory CD8T cell lineages in Interleukine 15 deficient mice. *J.Exp Med*. 2000; 191:771-80.
15. Zhang M, et al. Augmented IL15 (IL)n 15 Ra expression by CD40 activation is critical in synergistic CD8T cell-mediated antitumor activity of anti-CD40 antibody with IL 15 in Tramp-C2 tumors in mice. *J. Immunol*. 2012; 188: 6156-64.
16. Cooper MA, et al. Invivo evidence for a dependence on interleukin 15 for survival o Natural Killer Cells. *Blood*. 2002; 100: 3633-38.
17. Coulon KC, et al. Redistribution hyperproliferation, activation of natural killer cells and CD8T cells, and cytokine production during the first-in-human clinical trial of recombinant human interleukin 15 in patients with cancer. *J. Clin Oncol*. 2015; 33: 74-82.



The Natural Killer Cell in Anticancer Therapy - An Important Role for Natural Compounds

18. Chijoke O, Munz C. Dendritic cell-derived cytokine in human natural killer cell differentiation and activation. *Front Immunol.* 11 Nov 2013
19. Yoshihira Hayakawa et al. IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer cells ligands, alpha galactosylceramide. *Blood.* 1994.
20. Sorensen EW, Gerbes SA, Lord EM. IL12 suppresses Vascular Endothelium Growth Factor receptor 3 expression on tumor vessels by two distinct IFN- γ dependent mechanisms. *Journal of Immunology.* February 15, 2010; 184 (4): 1858-1866.
21. Hanke N, Alizadeh D, Larmoner N. Dendritic cell tumor-killing activity and its potential applications in cancer immunotherapy. *Crit Rev Immunol.* 2013; 33 (1): 1-21.
22. Clement MV, Haddah P, Scribe A. Involvement of granzyme and perforin gene expression in the lytic potential of human killer cells. *Res Immunol.* 1990;141: 477-89.
23. Osinsaka I, Popko K, Dembrow U. Perforin an important player in immune response. *Central Journal of Immunology.* 2014.
24. Thiery J, et al, Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells. *Nat Immunol.* 2011; 12:770-7.
25. Barg S, Seevasant I, Kamaral T. Potential of apoptotic pathway targeted cancer therapeutic research. Where do we start? *Cell Death-Disease.* 2016;7e 2058.
26. Mackenzie SH, Clark AC. Targeting cell death in Tumors by activating caspases. *Curr Cancer Drug Target.* March 8, 2008; (2): 98-109.
27. Tamin I, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. *Cancer Res.* Dec 1, 1998; 58 (23): 5315-20
28. Yong-Gang LU, Faabg Yu, Ling Wang. The role of survivin in diagnosis, prognosis, and treatment of breast cancer. *Journal of Thoracic Disease.* 2010 June; 2 (22): 100-110.
29. Jurasunas S. The Molecular Basis of Prostate Cancer and Targeting Therapies. *Townsend Letter.* August\Sept. 2017; 18-25.
30. Thorburn A. Tumor Necrosis Factor-Related Apoptosis-inducing Ligand (Trail) pathway signaling. *Journal of Thoracic Oncology.* June 1, 2007; 2 (6); P451-465.
31. Yagita H, et al. Trail and its receptors as a target for cancer therapy. *Cancer.* October 2004; 95 (10): 781.
32. Imai K, et al. Natural cytotoxic activity of peripheral blood lymphocytes and cancer incidence- an 11 year follow up study of the general population. *Lancet.* 2000;356: 1795-1799.
33. Mandal A, Viswanathan C. Natural killer cells in Health and Disease. *Hematology\Oncology and Stem Cell Therapy.* June 2015; 8 (2): 47-55.
34. Lopez.-Soto A, et al. Cont5ol of metastasis by NK cells. *Cancer Cells.* 2017; 32: 135-154.
35. Kogi D, et al. Cytotoxicity mediated by T-cells and natural killer cells is greatly impaired in perforin-deficient mice. *Nature.* 1994; 369-317.
36. Hanna N. Expression of metastatic potential of tumor in young nude mice correlated with low levels of natural killer cell-mediated cytotoxicity. *Int Journal of Cancer.* 1980;76: 675-80.
37. Zuhair M, Perrozmand HA. Evaluation of natural killer cell activity in pre and post-treated breast cancer patients. *Journal of Cancer Research and Therapeutics.* Oct/Nov 2010; 6 (4): 478-481.
38. Rios S, Francisco A, Cordon A, Nunez MI, Involvement of free radicals in breast cancer. *Springerphus.* 2013; 2: 404.
39. Nourazarian A, Kangari P, Salmaninejad A. Roles of oxidative stress in the development and progression of Breast Cancer. *Asian Pacific Journal of Cancer Prevention.* 2014;15 (2): 4745-4751.
40. Ben-Eliyahu S, Page GG, Yirmuya R, Shadkar G. Evidence that stress and surgical intervention promote tumor development by suppressing natural killer cell activity. *Int. J. Cancer.* 1999; 80 (6): 8808.

The Natural Killer Cell in Anticancer Therapy - An Important Role for Natural Compounds

41. Pollock RE, Lotzova E, Staanford SD. Mechanism of surgical stress impairment of human perioperative natural killer cell cytotoxicity. *Arch Surg.* 1991; 126 (3): 338-42.
42. Dervens S, et al. Oxidative stress especially downregulates survivin to promote breast cancer formation. *Bri Journal Cancer.* 2013;108 (4): 848-858.
43. Chen F, et al. New horizons in the tumor microenvironment, biology, challenge, and opportunities. *BMC Med.* 2015; 13-45.
44. Schulz M, et al. Microenvironmental regulator of the tumor progression and therapeutic response in brain metastases. *Front Immunol.* 2014; 10: 1713..
45. Pakiskrievicz CM, et al. T-regulatory cells and priming the suppressor tumor microenvironment. *Front Immunol.* 2014; 10: 24-53.
46. Takeski I, Hikata A, Inoue Y. The roles of TGF-B signaling in carcinogenesis and breast cancer metastasis. *Breast Cancer.* 2012;19:118-124.
47. Padra D, et al. TGF-B primes breast cancer for lung metastasis seeding through angiopoietin-like4. *Cell.* 2008; 133: 66-77.
48. Crane CA, et al. TGF-B downregulates the activating receptor NKG2D on NK and CD8+T cells in glioma patients. *Neuro-Oncol.* 2010; 12(1): 7-13.
49. Huakan Zhao, Lei, Wu, Yongsheng Li. Inflammation and tumor progression. Signaling pathway and targeted intervention. *Signal Transduction and Targeted Therapy.* Article number 263. (2001).
50. Sarkar S, et al. Hypoxia-induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL2 activation of NK cells. *Plos One.* May 28.2013.
51. Bonaventura P, et al. Cold tumors. A Therapeutic challenge for immunotherapy. *Front Immunol.* 2019; 10: 168.
52. Hau J, et al. TGF-B signaling and its targeting for glioma treatment. *American Journal of Cancer Research.* 2015; 5 (3): 945-955.
53. Lei Ji, Jungin Xu, Xiato LI. Mutant P53 promotes tumor cell malignancy by both positive and negative regulation to the Transforming Growth Factor B. (TGFB) pathway. *J Biological Chemistry.* May 1, 2015; 240 (18): 11729-11740.
54. Jurasunas S. The P53 Tumor suppressor gene. Understanding P53-Based Anticancer Therapy utilizing Dietary Agents. *Townsend Letter.* August\Sept 2015; 67-73.
55. Gang Gno et al. Local activation of P53 in the Tumor Microenvironment overcomes immune suppression and enhances Antitumor Immunity. *Cancer Res.* May 1, 2017; 77 (9): 2292-2305.
56. Li H, et al. Pharmacological activation of P53 triggers anticancer innate response through induction of ULBP2. *Cell Cycle.* 2011;10: 3346-3358.
57. Menendez D, Shatz M, Resnick M. Interactions between the tumor suppressor P53 and immune response. *Current Opinion in Oncology.* 2013;25 (1): 2387-96.
58. Tojyo I, et al. PD-L1 expression correlated with P53 expression in oral squamous cell carcinoma. *Maxillo-Plastic and Reconstructive Surgery.* Dec 2019; 41 (1): 56.
59. Gang Guo, et al. Local activation of P53 in the tumor microenvironment overcomes immune suppression and enhances antitumor response. *Cancer Res.* May 1, 2007; 77 (9): 2292-2305.
60. Li H. et al. Pharmacological activation of P53 triggers anticancer response through induction of ULBP2. *Cell Cycle.* 2011;10: 3346-3358.
61. Cozar B, et al. Tumor-infiltrating Natural Killer cells. *Cancer Discov.* 2021;11:1011. (AACR) online January 2022.
62. Sayid A, et al. Preferential accumulation of regulatory T-cells with highly immunosuppressive characteristics in breast cancer tumor microenvironment. *Oncotarget.* 2017; 8: 33159-33171.

The Natural Killer Cell in Anticancer Therapy - An Important Role for Natural Compounds

63. Liyanage UK, et al. Prevalence of regulatory T-cells is increased in peripheral blood and microenvironment of patients with pancreas and breast adenocarcinoma. *J Immunol.* September 2002; 196 (5): 2756-61.
64. Lissoni P, et al. Modulation of the anticancer immunity by natural agents, inhibition of T-regulatory lymphocyte generation by arabinoxylan in patients with locally limited or metastatic solid tumor. *Cancer Therapy.* 2008; 6: 1011-1016.
65. Moody R, et al. Natural compounds with the potential to modulate cancer therapies and self-reactive immune cells. *J Cancer.* 2020; 12 (3).
66. Nomenimovahed Z, Tiznobaik A, Salehiniya H. Ovarian cancer in the world epidemiology and Risk Factors. *Int Journal of Women's Health.* 2019; 11: 287-299.
67. Chi G, Chan AF. The effects of B-glucan on human immune and cancer cells. *Journal of Hematology Oncology.* 2009; Article number 25.
68. Guggehein AG, Wright KM, Zwickey HL. Immune Modulation From Five Major Mushroom, Application to Integrative Oncology. *Integrative Medicine.* Feb 2014; 13 (1).
69. Ghoneum M. Enhancement of natural killer cell activity of aged mice by model arabinoxylan rice bran (MGN3\Biobran) *Journal of Pharmacy and Pharmacology.* January 2005; 56 (12): 158-8.
70. Ghoneum M. From Bench to bedside. The growing use of Arabinoxylan Rice Bran (MGN3\Biobrab) in cancer immunotherapy. *Austin Immunol.* 2016; 1 (2).
71. Mamessier E, Sylvan A, Olive D. Human Breast cancer cells enhance self-tolerance by promoting evasion from NK cell antitumor immunity. *J. Clin Invest.* Sep 1, 2011; 121 (9): 3609-3622.
72. Soo Liang Ooi, et al. Arabinoxylan compound as a Complementary Therapy for Conventional Cancer Treatment. *Integrative Cancer Therapies.* 2018; 17 (2): 165-178.
73. Ghoneum M, Gollapudi S. Synergistic Apoptotic Effect of Arabinoxylan Rice Bran (MGN3\Biobran) and curcumin (Turmeric) on human multiple myeloma cell line U266 in vitro. *Neoplasma.* 2011; 58 (2).
74. Ghoneum. M. NK cell activation in a seven-year follow-up study. *Austin Immunology.* 2016.
75. Sarto T, et al. Development of hyporesponsiveness of natural killer cells to augmentation and activity after multiple treatments with biological response modifiers. *Cancer Immunology Immunother.* 1985; 19: 130-135.
76. Ghoneum M, Brwon J. NK immunorestitution of cancer patients by MGN3 modified arabinoxylan rice bran (study of 32 patients followed for up to 4 years). *Anti-Aging Medical Therapeutics.* Vol III. Klatz R, Goldman R 2000; 217-226.
77. Takahata K. Studies of life prolongation and QOL improvement Effects of RBAC for progressive cancer. Abstract 3rd Annual Meeting of Japanese Society for Complementary Medicine Treatment 2000.



TownsendLetter.com/get-involved